Angiogénesis Tumoral: estrategias diagnósticas y terapéuticas

Ximena Camacho; Pablo Cabral

doi:10.35954/SM2012.31.1.5

Autores

Ximena Camacho Departamento de Radiofarmácia, Centro de Pesquisa Nuclear, Faculdade de Ciências, Universidade da República (UdelaR). https://orcid.org/0000-0002-0755-3834
Pablo Cabral Departamento de Radiofarmacia, Centro de lnvestigaciones Nucleares, Facultad de Ciencias, Universidad de la Republica, Montevidéu, Uruguai. https://orcid.org/0000-0001-7344-2027

DOI:

https://doi.org/10.35954/SM2012.31.1.5

Palavras-chave:

Angiogênese tumoral; inibidores de angiogênese; VEGF.

Resumo

A angiogênese é fundamental para o desenvolvimento do tumor, e o período durante o qual ocorre a transição da fase do tumor avascular para a fase vascular é regulado pela expressão de fatores pró-angiogênicos como o fator de crescimento endotelial vascular (VEGF). Esta substância é uma glicoproteína que é produzida tanto por células normais quanto neoplásicas e desempenha um papel importante tanto em situações fisiológicas quanto patológicas. A ligação do VEGF a seus receptores leva ao recrutamento de sinais moleculares intracelulares responsáveis pela sobrevivência celular, permeabilidade vascular, migração e proliferação. Muitos estudos têm descrito a relação entre a expressão VEGF e o prognóstico do paciente em patologias oncológicas. Tanto o VEGF quanto seus receptores têm sido alvos para o desenvolvimento de numerosos agentes terapêuticos e de diagnóstico. Este documento descreve alguns desses agentes, bem como suas estratégias e/ou mecanismos para visar ou inibir a angiogênese tumoral.

Recebido para revisão: junho de 2012.
Aceito para publicação: Agosto de 2012.

Downloads

Não há dados estatísticos.

Métricas

Carregando Métricas ...

Referências

(1) Dvorak HF. Angiogenesis update 2005. Thromb Haemost 2005; 3:1835-1842.

(2) Ferrara N, Gerber HP, LeCounter J. The biology of VEGF and its receptors. Nat Med 2003; 9(6): 669-676.

(3) Hunter J. Lectures on the Principles of Surgery in the Works of John Hunter, ed. J. F. Palmer, vol.1, p.220. London : Longman, sf. p 220.

(4) Virchow R, Die. Krankhaften Geschwulste. Berlin : August Hirschwald, 1863.

(5) Goldman E. The growth of malignant disease in man and the lower animals with special reference to the vascular system. Lancet 1907; 2:1236-40.

(6) Clark ER, et al. General observations on the ingrowth of new blood vessels into standardized chambers in the rabbit’s ear, and the subsequent changes in the newly grown vessels over a period of months. Anat Rec 1931; 50:129-67.

(7) Clark ER, Clark EI. Microscopic observations on the growth of blood capillaries in the living mammals. Am J Anat 1939; 64:251-301.

(8) Ide AG, Baker NH, Warren, et al. Vascularization of the Brown-Pearce rabbit epithelioma transplant as seen in the transparent ear chamber. Am J Roentgenol 1939; 32:891-9.

(9) Algire GH, Chalkley HW. Vascular reactions of normal and malignant tissue in vivo. J Natl Cancer Inst 1945; 6:73-85.

(10) Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285:1182–1186.

(11) Figg WD, Folkman J. Angiogenesis: an integrative approach from science to medicine. New York: Springer, 2008.

(12) Folkman J. Angiogenesis research: from laboratory to clinic. Forum (Geneva) 1999; 9:3 (3 Suppl):59-62.

(13) Dvorak HF, et al. Vascular permeability factor/ vascular endothelial growth factor and the significance on microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Inmunol 1999; 237:97-132.

(14) Shibuya M. Structure and fuction of VEGF/VEGF- receptor system involved in angiogenesis. Cell Struct Funct 2001; 26:25-35.

(15) Partanen TA, Paavonen K. Lymphatic versus blood vascular endothelial growth factors and receptors in humans. Microsc Res Tech 2001; 55:108-121.

(16) Houck KA, et al. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991; 5:1806-1814.

(17) De Vries C, et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992; 255: 989-991.

(18) Veikkola T, et al. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000; 60:203-212.

(19) Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS 2005; 9:209-31.

(20) Holash J, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284:1994-8.

(21) Ruhrberg C. Endogenous inhibitors of angiogenesis. J Cell Sci 2001; 114:3215-6.

(22) Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972; 175:409-16.

(23) Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82:4- 6.

(24) Carmeliet P; Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407:249-57.

(25) Ribatti D. The involvement of endothelial progenitor cells in tumor angiogenesis. J Cell Mol Med 2004; 8:294- 300.

(26) Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorogenesis. Cell 1996; 86:353-64.

(27) Folkman J, et al. Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost 2001; 86:23-33.

(28) Moeller BJ, et al. The relationship between hypoxia and angiogenesis. Semin Radiat Oncol 2004;14:215-21.

(29) Semenza G. Angiogenesis in ischemic and neoplastic disorders. Annu Rev Med 2003; 54:17-28.

(30) Goodsell D. The molecular perspective: VEGF and angiogenesis. Stem Cells 2003; 21: 118-119.

(31) Zetter B. Angiogenesis and tumor metastasis. Annu Rev Med 1998; 49:407-424.

(32) Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438:932-36.

(33) Risau W. Mechanism of angiogenesis. Nature 1997; 386:671-74.

(34) Ferrara N. Role of vascular endothelial growth factor in physiologic and patholgic angiogenesis: therapeutic implications. Semin Oncol 2002; 29(6):10-14.

(35) Dvorak HF, Rons-Whipple A. How tumors make bad blood vessels and stroma. Am J Pathol 2003;162:1747- 57.

(36) Folkman J. Fundamental concepts of the angiogenesis process. Curr Mol Med 2003, 3: 643-51.

(37) Ingber D, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990; 348:555-7.

(38) Hurwitz H, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.

(39) Hida K, et al. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 2004; 64:8249-55.

(40) Yu JL, et al. Effect of p53 status on tumor response to antiangiogenic therapy. Science 2002; 295:1526-8.

(41) Ferrara N, Kerbel R. Angiogenesis as a therapeutic target. Nature 2005; 438: 967-74.

(42) Ferrando NH, Hurwitz HI. Targeted therapy of colorectal cancer: clinical experience with bevacizumab. The Oncologist 2004; 9(1): 11-18.

(43) Presta LG, et al. Humanization of an anti-vascular endotelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57:4593-99.

(44) Lee CG, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000; 60:5565-70.

(45) Prewett M, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999; 59: 5209-18.

(46) Mendel DB, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet- derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9(1):327-37.

(47) Wood JM, et al. PTK787/ ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60:2178-89.

(48) Pietras R, Weinberg O. Antiangiogenic Steroids in Human Cancer Therapy. ECAM 2005; 2(1): 49–57.

(49) Bikfalvi A, Bicknell R. Recent advances in angiogenesis, anti-angiogenesis and vascular targeting. Trends Pharmacol Sci 2002; 23(12): 576-82.

(50) Zhu Z, Witte L. Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor. Invest New Drugs 1999; 17: 195-212.

(51) Weissleder R, Mahmood U. Molecular Imaging. Radiology 2001; 219:316- 33.

(52) Blankenberg FG, et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci 1998; 95:6349–54.

(53) Miles K A. Perfusion CT for the assessment of tumour vascularity: which protocol? British Journal of Radiology 2003; 76: 36-42.

(54) Maria Moresco R, et al. PET in psychopharmacology. Pharmacol Res 2001; 44:151–9.

(55) Eleta F, et al. Imágenes moleculares: morfología y función. Rev Argent Radiol 2004; 68: 201-22.

(56) Cai W, et al. Positron emission tomography imaging of vascular endothelial growth factor receptor expression. J Nucl Med 2006; 47 (12): 2048-56.

(57) Cornelissen B, et al. In vitro and in vivo evaluation of [123I]-VEGF165 as a potential tumor marker. Nucl Med Biol 2005; 32:431–6.

(58) Cornelissen B, et al. In vitro and in vivo evaluation of [123I]-VEGF165 as a potential tumor marker. Nucl Med Biol 2005; 32:431–6.

(59) Jayson GC, et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Nat Cancer Inst 2002; 94:1484–93.

(60) Goncalves M, et al. Design, synthesis, and evaluation of original carriers for targeting vascular endothelial growth factor receptor interactions. Pharm Res 2005; 22:1411–21.

(61) Camacho X, et al. [99mTc(CO)3]-Radiolabeled Bevacizumab: In vitro and in vivo evaluation in a Melanoma model. Oncology, “in press”; DOI: 10.1159/000338961.

(62) Janssen ML, et al. Tumor targeting with radiolabeled avh3 integrin binding peptides in a nude mouse model. Cancer Res 2002; 62:6146–51.

(63) Line BR, et al. Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates. J Nucl Med 2005; 46:1552–60.

(64) Haubner R, et al. Noninvasive imaging of avh3 integrin expression using 18F-labeled RGD-containing glycopeptides and positron emission tomography. Cancer Res 2001; 61:1781–5.

(65) Chen X, et al. MicroPET and autoradiographic imaging of breast cancer av-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjug Chem 2004;15:41–9

(66) Chen X, et al. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor avh3-integrin expression. J Nucl Med 2004; 45:1776–83.

(67) Cai W, et al. In vitro and in vivo characterization of 64Cu-labeled Abegrin2, a humanized monoclonal antibody against integrin αvβ3. Cancer Res 2006; 66:9673–81.

(68) Furumoto S, et al. Tumor detection using 18F-labeled matrix metalloproteinase-2 inhibitor. Nucl Med Biol 2003; 30:119–25.

(69) Giersing BK, et al. Synthesis and characterization of 111In-DTPA-N-TIMP-2: a radiopharmaceutical for imaging matrix metalloproteinase expression. Bioconjug Chem 2001; 12:964–71.

(70) Oltenfreiter R, et al. New radioiodinated carboxylic and hydroxamic matrix metalloproteinase inhibitor tracers as potential tumor imaging agents. Nucl Med Biol 2004; 31:459–68.

(71) Sprague JE, et al. In vitro and in vivo investigation of matrix metalloproteinase expression in metastatic tumor models. Nucl Med Biol 2006; 33:227–37.